Tuesday, February 24, 2015 8:40:17 AM
With the singular exception of the way the Cohort 2 results were released the GALT management team has done an outstanding job of bringing GR-MD-02 to the start of Phase 2.
The Phase 2 trial(s) are going to focus on changes in portal hypertension (with the blessing of the FDA) as the endpoint. That is very significant since their successful animal trials (which reversed fibrosis) were based in large part on the same end point.
It doesn't matter what amateurs like Feuerstein believe regarding liver biopsies or anything else, the FDA is the final judge on any trial and having them on board with this design is absolutely critical to eventual approval.
When you look back on the development of this drug it is clear that Traber and his team knew exactly what they were doing at the beginning of the pre-clinical trials and they have enough money to complete all this with no further dilution.
As for the lawsuits (if they ever develop), they are based on GALT misleading the public and it's entirely possible that the Phase 2-FX shorter trial is targeted in part to end this.
If you also look at the Cohort 3 results, the changes in both Fibrotest and Alpha-2 macroglobulin after the 4th dose and 14 days are almost stunning in the way they improved-Phase 2 has 26 doses and you would have to think that the longer this is in the system the more it will help both slow down and possibly reverse advanced fibrosis.
I am of the very strong belief that GR-MD-02 will eventually be approved since the bar for approval (slow down the development of Fibrosis) is so low; they don't have to show reversal, just extending life a few years would be reason enough to approve the drug since there is no other treatment.
I hold more shares now than I did in mid-2014, the only change I made was to sell off GALTW and replace them with GALT common shares to account for the longer time period before potential approval, which will probably go past the expiration of the warrants.
I have no explanation for why the share price continues to hover between $3 and $4 and, while it is frustrating, it doesn't matter in the long run, at least to me.
Recent GALT News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 12:08:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:55:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 11:50:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 12:41:21 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 12:38:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 11:50:32 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 07/23/2024 01:43:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/23/2024 01:38:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/20/2024 05:55:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:55:18 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 11:50:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 05:50:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:55:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:53:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:52:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:51:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:50:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:48:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:47:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:46:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:44:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:43:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:40:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 04:23:48 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM